Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23517184 | 0.82 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL27015414 | 0.82 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL2552268 | 0.81 | BACE1 (0.42) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL4113194 | 0.81 | BACE1 (0.42) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL18603407 | 0.81 | BACE1 (0.42) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL3580266 | 0.81 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL25301499 | 0.81 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL3579416 | 0.80 | NPC1 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL16876936 | 0.76 | DUT (0.31) | — | |
| SCHEMBL29991616 | 0.75 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304412-B2 | Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304412-B2 | Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2099788-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008064788-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | QDPR, TPMT, PTGIS | SMYD2 1968/4885CYP3A4 442/4885HTT 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.